Evaluation of miRNAs 9 and 342 expressions in sera as diagnostic and prognostic biomarkers for breast cancer.

Breast Disease
Heba A EwidaMae Seleem

Abstract

Molecular markers for the detection of breast cancer and its different types, grades, and stages lack enough sensitivity and specificity. This study evaluates the expression of miRNAs 9 and 342 in sera of different types, grades, and stages of BC. Moreover, the assessment of their sensitivity, specificity, diagnostic, and prognostic role in detecting different types of BC. Blood was collected from 200 females outpatients, divided into five groups each 40 subjects: control, benign breast tumor, estrogen receptor (ER+)/progesterone receptor (PR+) BC, human epidermal growth factor receptor (HER+) BC, and triple-negative BC. BC subjects were further subdivided according to grade and stage. Expressions of miRNAs 9 and 342 were measured for all subjects by real-time polymerase chain reaction (RT-PCR). Results showed that serum expression of both miRNAs 9 and 342 can be used for the diagnosis of different types of BC. Their expression can be used to significantly differentiate between different grades and stages of BC. MiRNAs 9 and 342 showed high sensitivity of 92.5% and specificity of (81.2 and 88.7%), respectively, for triple-negative BC. The expressions of miRNAs 9 and 342 provide potential roles as serological biomarkers for the ...Continue Reading

References

Aug 30, 2000·Nature·C M PerouD Botstein
Apr 4, 2006·Cancer Biology & Therapy·Gloria RoldánIgnacio Miguel Musé
Feb 19, 2008·Cancer Research·David SarrióJosé Palacios
Feb 23, 2010·Nature Cell Biology·Li MaRobert A Weinberg
Feb 25, 2010·Annals of Surgical Oncology·Stephen B Edge, Carolyn C Compton
May 1, 2010·Nucleic Acids Research·Carla BurrowsSarah P Blagden
May 22, 2010·Journal of Mammary Gland Biology and Neoplasia·Douglas S MicalizziHeide L Ford
Jan 29, 2011·Cell Cycle·Jelena RadojicicEfstathios N Stathopoulos
Apr 12, 2012·Molecular Diagnosis & Therapy·Jonathan KrellLeandro Castellano
May 29, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Shahram SavadMohammad Hossein Modarressi
Sep 20, 2012·Methods : a Companion to Methods in Enzymology·Serena VinciClaudio Orlando
Feb 15, 2013·Experimental and Therapeutic Medicine·Yue-Jun HeJin-Hai Tang
Nov 12, 2013·Journal of the Egyptian National Cancer Institute·Ahmed A ZeeneldinEhab Mosaad
Jan 30, 2014·PloS One·Elisabetta CrippaMarco Alessandro Pierotti
Jan 11, 2016·Cancer Science·Akihiko ShimomuraTakahiro Ochiya
Oct 30, 2016·Molecular and Cellular Probes·Aisan HasanzadehMahboobeh Madani
Nov 21, 2017·Biomarkers in Medicine·Yunjie HeJinhai Tang
Jan 13, 2018·PloS One·Hsiu-Pei TsaiShin-Cheh Chen
Aug 26, 2018·Clinical Breast Cancer·Ola S AliDalia O Makhlouf
Nov 2, 2018·Scientific Reports·Srinivasulu Yerukala Sathipati, Shinn-Ying Ho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.